Aripiprazole Tablet
Product Images NDC 50228-330

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 50228-330). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sciegen Pharmaceuticals Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

10mg-30 (Aripiprazole Blister10mg)

Packaging label sheet showing multiple boxes of Aripiprazole orally disintegrating tablets, USP, 10 mg strength. The labels include instructions not to push tablets through foil, manufacturer ScieGen Pharmaceuticals Inc, and space for lot number and expiration date. The layout contains four identical label blocks per column, each repeated five times horizontally.*

FDA Label Image

15mg-30tab (Aripiprazole Blister15mg)

Label for Aripiprazole orally disintegrating tablets, USP, available in strengths of 10 mg and 15 mg. The label includes dosage instructions, manufacturer information as ScieGen Pharmaceuticals Inc, lot number, and expiration date fields. The packaging features multiple labels arranged in columns, each with similar text and barcodes.*

FDA Label Image

10mg-30tab (Aripiprazole Cartonlabel3)

Packaging label for Aripiprazole Orally Disintegrating Tablets, USP, 10 mg. The label shows a carton containing 30 unit-dose tablets (3 x 10) manufactured by ScieGen Pharmaceuticals Inc. It includes storage instructions, dosage form, strength, and a barcode. The product is Rx only and specifies that each orally disintegrating tablet contains 10 mg aripiprazole.*

FDA Label Image

15mg-30tab (Aripiprazole Cartonlabel4)

Packaging label for Aripiprazole Orally Disintegrating Tablets, USP, 15 mg, manufactured by ScieGen Pharmaceuticals Inc. The label indicates the product contains 30 (3 x 10) unit-dose tablets, for oral use by prescription only. Storage instructions and usage precautions are included on the label.*

FDA Label Image

Figure-1.jpg (Aripiprazole Figure1)

A plot showing the effect of various drugs on Aripiprazole pharmacokinetics, specifically fold change and 90% confidence intervals for AUC and Cmax. The chart compares changes relative to a reference without interacting drug for CYP3A4 inhibitor ketoconazole, CYP2D6 inhibitor quinidine, CYP3A4 inducer carbamazepine, gastric acid blockers famotidine, and other drugs valproate, lithium, and lorazepam.*

FDA Label Image

Figure-2.jpg (Aripiprazole Figure2)

A pharmacokinetic chart titled 'Effect of Other Drugs on Aripiprazole' showing the fold change and 90% confidence interval for Dehydro-Aripiprazole with various interacting drugs. The x-axis represents change relative to reference (without interacting drug), and the y-axis lists drug categories including CYP3A4 inhibitors, CYP2D6 inhibitors, CYP3A4 inducers, gastric acid blockers, and other drugs. Data points illustrate AUC and Cmax changes with ketoconazole, quinidine, carbamazepine, famotidine, valproate, lithium, and lorazepam.*

FDA Label Image

Figure-3.jpg (Aripiprazole Figure3)

A chart titled 'Effect of Aripiprazole on Other Drugs' showing fold change and 90% confidence intervals for various drugs metabolized by enzymes CYP2D6, CYP2C9, 2C19, and UGT1A4. The vertical axis lists drugs including dextromethorphan, warfarin (S- and R-forms), omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, desmethylvenlafaxine, and escitalopram, with pharmacokinetic parameters AUC and Cmax indicated. The horizontal axis measures change relative to reference without interacting drug, ranging from 0 to 3, illustrating the impact of aripiprazole on these drugs' pharmacokinetics.*

FDA Label Image

Figure-4.jpg (Aripiprazole Figure4)

A pharmacokinetic chart titled 'Aripiprazole Fold Change and 90% CI' showing the fold change in AUC and Cmax for Aripiprazole in various special populations, including CYP2D6 metabolism status, gender, age groups, hepatic impairment (mild, moderate, severe), and severe renal impairment. The x-axis represents change relative to reference, ranging approximately from 0.5 to 3.0.*

FDA Label Image

Figure-5.jpg (Aripiprazole Figure5)

A fold change chart illustrating Dehydro-Aripiprazole with 90% confidence intervals comparing pharmacokinetic values (AUC and Cmax) across different groups: CYP2D6 poor versus extensive metabolizers, female versus male, age groups 18-64 versus over 65, hepatic impairment (mild, moderate, severe versus normal), and severe renal impairment. The x-axis shows the change relative to reference values.*

FDA Label Image

Figure-6.jpg (Aripiprazole Figure6)

A line graph showing the proportion of subjects with relapse over time in days from randomization for Aripiprazole and placebo groups. The x-axis represents days up to 182, and the y-axis shows the proportion with relapse from 0 to 1. Aripiprazole has a lower relapse proportion compared to placebo. A table beneath the graph displays the number of subjects at risk at several time points for each group.*

FDA Label Image

Figure 7 (Aripiprazole Figure7)

A Kaplan-Meier curve comparing the proportion with relapse over days from randomization between Aripiprazole oral disintegrating tablet and placebo groups. The x-axis represents days (0 to 182), and the y-axis shows the proportion with relapse (0 to 1.0). The graph includes the number of subjects at risk at various time points for both groups.*

FDA Label Image

Figure 8 (Aripiprazole Figure8)

A line graph comparing the proportion with relapse over time in days from randomization between Aripiprazole and placebo groups. The x-axis shows days from 0 to 364, with numbers of subjects at risk listed below. The y-axis represents the proportion with relapse from 0 to 1. Two lines plot relapse proportion, with Aripiprazole showing a consistently lower relapse rate than placebo.*

FDA Label Image

10mg-30 (Aripiprazole Label1)

Label for Aripiprazole Orally Disintegrating Tablets, USP 10 mg by ScieGen Pharmaceuticals Inc. The label indicates each tablet contains 10 mg aripiprazole. It includes dosage, storage instructions, and warnings, with a pack size of 30 tablets. The label shows the NDC 50228-330-30 and bar code, along with lot and expiration date fields.*

FDA Label Image

15mg-30 (Aripiprazole Label2)

Label for Aripiprazole Orally Disintegrating Tablets, USP 15 mg oral tablets. The package contains 30 tablets and is labeled for prescription use only. Manufactured by ScieGen Pharmaceuticals Inc. The label includes storage instructions and a barcode.*

FDA Label Image

Structural Formula (Aripiprazole Structure)

Chemical structure of aripiprazole as shown in the image, depicting its molecular arrangement with two chlorine atoms, a piperazine ring, and a quinolinone moiety.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.